Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors

David E Piccioni; Achal Singh Achrol; Lesli A Kiedrowski; Kimberly C Banks; Najee Boucher; Garni Barkhoudarian; Daniel F Kelly; Tiffany Juarez; Richard B Lanman; Victoria M Raymond; Minhdan Nguyen; Judy D Truong; Annie Heng; Jaya Gill; Marlon Saria; Sandeep C Pingle; Santosh Kesari

doi:10.2217/cns-2018-0015

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors

David E Piccioni, Achal Singh Achrol, Lesli A Kiedrowski, Kimberly C Banks, Najee Boucher, Garni Barkhoudarian, Daniel F Kelly, Tiffany Juarez, Richard B Lanman, Victoria M Raymond, Minhdan Nguyen, Judy D Truong, Annie Heng, Jaya Gill, Marlon Saria, Sandeep C Pingle, Santosh Kesari

Research output: Contribution to journal › Article › peer-review

117 Scopus citations

Abstract

Aim: Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate genomic interrogation in these patients. Methods: Data from 419 PBT patients tested clinically with a ctDNA NGS panel at a CLIA-certified laboratory were analyzed. Results: A total of 211 patients (50%) had ≥1 somatic alteration detected. Detection was highest in meningioma (59%) and gliobastoma (55%). Single nucleotide variants were detected in 61 genes, with amplifications detected in ERBB2, MET, EGFR and others. Conclusion: Contrary to previous studies with very low yields, we found half of PBT patients had detectable ctDNA with genomically targetable off-label or clinical trial options for almost 50%. For those PBT patients with detectable ctDNA, plasma cfDNA genomic analysis is a clinically viable option for identifying genomically driven therapy options.

Original language	American English
Journal	CNS oncology
Volume	8
Issue number	2
DOIs	https://doi.org/10.2217/cns-2018-0015
State	Published - Mar 11 2019

Keywords

cell-free DNA
ctDNA
genomic profiling
glioblastoma
Guardant360
liquid biopsy
personalized medicine
primary brain tumors

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.2217/cns-2018-0015License: Unspecified

Cite this

Piccioni, D. E., Achrol, A. S., Kiedrowski, L. A., Banks, K. C., Boucher, N., Barkhoudarian, G., Kelly, D. F., Juarez, T., Lanman, R. B., Raymond, V. M., Nguyen, M., Truong, J. D., Heng, A., Gill, J., Saria, M., Pingle, S. C., & Kesari, S. (2019). Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS oncology, 8(2). https://doi.org/10.2217/cns-2018-0015

@article{e35b1e7270564ba8b14072babc97aa6c,

title = "Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors",

abstract = "Aim: Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate genomic interrogation in these patients. Methods: Data from 419 PBT patients tested clinically with a ctDNA NGS panel at a CLIA-certified laboratory were analyzed. Results: A total of 211 patients (50%) had ≥1 somatic alteration detected. Detection was highest in meningioma (59%) and gliobastoma (55%). Single nucleotide variants were detected in 61 genes, with amplifications detected in ERBB2, MET, EGFR and others. Conclusion: Contrary to previous studies with very low yields, we found half of PBT patients had detectable ctDNA with genomically targetable off-label or clinical trial options for almost 50%. For those PBT patients with detectable ctDNA, plasma cfDNA genomic analysis is a clinically viable option for identifying genomically driven therapy options.",

keywords = "cell-free DNA, ctDNA, genomic profiling, glioblastoma, Guardant360, liquid biopsy, personalized medicine, primary brain tumors",

author = "Piccioni, {David E} and Achrol, {Achal Singh} and Kiedrowski, {Lesli A} and Banks, {Kimberly C} and Najee Boucher and Garni Barkhoudarian and Kelly, {Daniel F} and Tiffany Juarez and Lanman, {Richard B} and Raymond, {Victoria M} and Minhdan Nguyen and Truong, {Judy D} and Annie Heng and Jaya Gill and Marlon Saria and Pingle, {Sandeep C} and Santosh Kesari",

note = "cookie policy. ×",

year = "2019",

month = mar,

day = "11",

doi = "10.2217/cns-2018-0015",

language = "American English",

volume = "8",

journal = "CNS oncology",

number = "2",

}

Piccioni, DE, Achrol, AS, Kiedrowski, LA, Banks, KC, Boucher, N, Barkhoudarian, G , Kelly, DF , Juarez, T, Lanman, RB, Raymond, VM, Nguyen, M , Truong, JD, Heng, A, Gill, J, Saria, M, Pingle, SC & Kesari, S 2019, 'Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors', CNS oncology, vol. 8, no. 2. https://doi.org/10.2217/cns-2018-0015

TY - JOUR

T1 - Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors

AU - Piccioni, David E

AU - Achrol, Achal Singh

AU - Kiedrowski, Lesli A

AU - Banks, Kimberly C

AU - Boucher, Najee

AU - Barkhoudarian, Garni

AU - Kelly, Daniel F

AU - Juarez, Tiffany

AU - Lanman, Richard B

AU - Raymond, Victoria M

AU - Nguyen, Minhdan

AU - Truong, Judy D

AU - Heng, Annie

AU - Gill, Jaya

AU - Saria, Marlon

AU - Pingle, Sandeep C

AU - Kesari, Santosh

N1 - cookie policy. ×

PY - 2019/3/11

Y1 - 2019/3/11

N2 - Aim: Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate genomic interrogation in these patients. Methods: Data from 419 PBT patients tested clinically with a ctDNA NGS panel at a CLIA-certified laboratory were analyzed. Results: A total of 211 patients (50%) had ≥1 somatic alteration detected. Detection was highest in meningioma (59%) and gliobastoma (55%). Single nucleotide variants were detected in 61 genes, with amplifications detected in ERBB2, MET, EGFR and others. Conclusion: Contrary to previous studies with very low yields, we found half of PBT patients had detectable ctDNA with genomically targetable off-label or clinical trial options for almost 50%. For those PBT patients with detectable ctDNA, plasma cfDNA genomic analysis is a clinically viable option for identifying genomically driven therapy options.

AB - Aim: Genomically matched trials in primary brain tumors (PBTs) require recent tumor sequencing. We evaluated whether circulating tumor DNA (ctDNA) could facilitate genomic interrogation in these patients. Methods: Data from 419 PBT patients tested clinically with a ctDNA NGS panel at a CLIA-certified laboratory were analyzed. Results: A total of 211 patients (50%) had ≥1 somatic alteration detected. Detection was highest in meningioma (59%) and gliobastoma (55%). Single nucleotide variants were detected in 61 genes, with amplifications detected in ERBB2, MET, EGFR and others. Conclusion: Contrary to previous studies with very low yields, we found half of PBT patients had detectable ctDNA with genomically targetable off-label or clinical trial options for almost 50%. For those PBT patients with detectable ctDNA, plasma cfDNA genomic analysis is a clinically viable option for identifying genomically driven therapy options.

KW - cell-free DNA

KW - ctDNA

KW - genomic profiling

KW - glioblastoma

KW - Guardant360

KW - liquid biopsy

KW - personalized medicine

KW - primary brain tumors

UR - https://www.futuremedicine.com/doi/pdf/10.2217/cns-2018-0015

UR - http://www.scopus.com/inward/record.url?scp=85068719589&partnerID=8YFLogxK

U2 - 10.2217/cns-2018-0015

DO - 10.2217/cns-2018-0015

M3 - Article

C2 - 30855176

VL - 8

JO - CNS oncology

JF - CNS oncology

IS - 2

ER -

Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors

Abstract

Keywords

Disciplines

Access to Document

Other files and links

Fingerprint

Cite this